Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
June 10, 2019 07:23 ET
|
Aptinyx Inc.
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with...
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 14, 2019 06:27 ET
|
Aptinyx Inc.
Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill., May 14, 2019 ...
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
May 07, 2019 07:23 ET
|
Aptinyx Inc.
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
May 06, 2019 07:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
April 30, 2019 07:27 ET
|
Aptinyx Inc.
Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at...
Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study
April 18, 2019 07:27 ET
|
Aptinyx Inc.
Mechanism of NYX-2925 is highly relevant in advanced DPN patients with longer duration of chronic pain Results support and inform future Phase 2 study, initiation expected in 2019 ...
Aptinyx to Present at 18th Annual Needham Healthcare Conference
April 04, 2019 08:00 ET
|
Aptinyx Inc.
EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458
April 03, 2019 07:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., April 03, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
March 28, 2019 07:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
March 22, 2019 07:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...